ArticleDermatologic therapy2021
Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
Article in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Plasmapheresis for Facilitating Readministration of Rituximab After Paradoxical Exacerbation in Pemphigus Vulgaris: A Case Report.Clinical case reports · 2025Article
- Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.Frontiers in medicine · 2023Review
- Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.Frontiers in medicine · 2023Article
- Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.Journal of clinical medicine · 2022Review
- COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.Dermatologic therapy · 2022Article
- Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?Dermatologic therapy · 2021Article
- Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.Frontiers in immunology · 2021Article
- Experience of Rituximab Therapy in Pemphigus: A Three-Year Retrospective Study from a Sub-Himalayan State.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab is a monoclonal antibody that targets CD20, a B-lymphocyte antigen; that leads to a decline in the B-cell counts for at least a year. The patients who have received rituximab treatment in the previous 5 years with the diagnosis of pemphigus group of diseases at Cerrahpaşa Medical Faculty were questioned for COVID-19 infection. A total of 48 patients were included in this study; only one male patient had COVID-19 infection which had a mild course. There is no significant difference in the total number of lymphocytes between patients who have received rituximab within the previous 5 years or last year. The number of lymphocytes is independent of the number of courses of rituximab treatment received. Therefore, we suggest that all pemphigus patients who have received rituximab treatment within the previous 5 years should be careful of the preventive measures against the COVID-19 infection irrespective of the number of treatment courses or the number of years which has passed since the treatment. The disease course was mild in the only infected patient. Thus, rituximab may be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic if its use is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.